★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
Applied Sciences OPEN ACCESS

Advances in ß-Thalassemia: From Molecular Biology to Clinical Practice

Pragya Mishra
Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh, India
Sayali Mukherjee
Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh, India
DOI Crossref DOI 10.37547/tajas/warm-34
tajas 2026
JOURNAL PUBLICATION MAY
VOLUME —
ISSUE —
YEAR 2026
PAGES 391-404

Abstract

Beta-thalassemia (ß-thalassemia) is an autosomal recessive disorder of haemoglobin inheritance resulting due to mutations of HBB gene present on chromosome 11 that lead to quantitative deficiency of ß-globin chains. The defect results in the accumulation of unpaired α-globin chains, inducing high rates of apoptosis in erythroid precursors, ineffective erythropoiesis, severe anaemia and progressive systemic iron overload. The conventional clinical approach is lifelong blood transfusion with regular iron chelation therapy but patients remain at risk of secondary organ toxicity. This review delineates the rapid paradigm shift in management of ß-thalassemia from conventional, supportive strategies toward personalised precision medicine. It discusses critical modern diagnostic methodologies, such as high- performance liquid chromatography (HPLC) and multiplex ligation-dependent probe amplification (MLPA), alongside pioneering therapeutic interventions. This paper reviews the clinical efficacy, regulatory milestones and mechanisms of action of the recently FDA-approved autologous hematopoietic stem cell gene therapies and CRISPR/Cas9-based gene-editing systems. It also discusses new targeted drug therapies and novel hepcidin-ferroportin axis modulators. It highlights important implementation challenges, including high costs of treatment, disparities in access across the world, and the integration of multi-omics data, and emphasizes the pathways needed to translate these advanced genomic innovations into accessible curative clinical standards on a global scale.

Keywords

ß-thalassemia iron chelation therapy precision medicine targeted drug therapies

Downloads

Download data is not yet available.

References

  1. Weatherall, D. J., & Clegg, J. B. (2001). The Thalassaemia Syndromes (1st ed.). Wiley. https://doi.org/10.1002/9780470696705
  2. Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet Journal of Rare Diseases, 5(1), 11. https://doi.org/10.1186/1750-1172-5-11
  3. Origa, R. (2017). β-Thalassemia. Genetics in Medicine, 19(6), 609–619. https://doi.org/10.1038/gim.2016.173
  4. Tuo, Y., Li, Y., Li, Y., Ma, J., Yang, X., Wu, S., Jin, J., & He, Z. (2024). Global, regional, and national burden of thalassemia, 1990–2021: A systematic analysis for the global burden of disease study 2021. eClinicalMedicine, 72, 102619. https://doi.org/10.1016/j.eclinm.2024.102619
  5. Sumedha, D., & Anita, K. (2023). Prevalence of beta thalassemia carriers in India: A systematic review and meta-analysis. Journal of Community Genetics, 14(6), 527–541. https://doi.org/10.1007/s12687-023-00683-7
  6. Singh, P., Shaikh, S., Parmar, S., & Gupta, R. (2023). Current Status of β-Thalassemic Burden in India. Hemoglobin, 47(5), 181–190. https://doi.org/10.1080/03630269.2023.2269837
  7. Rund, D., & Rachmilewitz, E. (2005). β-Thalassemia. New England Journal of Medicine, 353(11), 1135–1146. https://doi.org/10.1056/NEJMra050436
  8. Cao, A., & Kan, Y. W. (2013). The Prevention of Thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(2), a011775–a011775. https://doi.org/10.1101/cshperspect.a011775
  9. Modell, B. (2008). Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 2008(6), 480–487. https://doi.org/10.2471/BLT.06.036673
  10. Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018). Thalassaemia. The Lancet, 391(10116), 155–167. https://doi.org/10.1016/S0140-6736(17)31822-6
  11. Cappellini, M. D., Cohen, A., Porter, J., Taher, A., & Viprakasit, V. (Eds.). (2014). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) (3rd ed.). Thalassaemia International Federation. http://www.ncbi.nlm.nih.gov/books/NBK269382/
  12. Porter, J. B. (2001). Practical management of iron overload. British Journal of Haematology, 115(2), 239–252. https://doi.org/10.1046/j.1365-2141.2001.03195.x
  13. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M. D., Del Vecchio, G. C., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., Piga, A., & Cnaan, A. (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89(10), 1187–1193.
  14. Thein, S. L. (2013). The Molecular Basis of -Thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(5), a011700–a011700. https://doi.org/10.1101/cshperspect.a011700
  15. Musallam, K. M., Cappellini, M. D., Porter, J. B., Farmakis, D., Eleftheriou, A., Angastiniotis, M., & Taher, A. T. (2025). TIF Guidelines for the Management of Transfusion‐Dependent β‐Thalassemia. HemaSphere, 9(3), e70095. https://doi.org/10.1002/hem3.70095
  16. American Family Physician. (n.d.).
  17. Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., Ibrahim, M., & Hassan, H. A. (2024). Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment. Thalassemia Reports, 14(4), 81–102. https://doi.org/10.3390/thalassrep14040010
  18. Giardine, B., Borg, J., Viennas, E., Pavlidis, C., Moradkhani, K., Joly, P., Bartsakoulia, M., Riemer, C., Miller, W., Tzimas, G., Wajcman, H., Hardison, R. C., & Patrinos, G. P. (2014). Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Research, 42(Database issue), D1063-1069. https://doi.org/10.1093/nar/gkt911
  19. Viprakasit, V., Gibbons, R. J., Broughton, B. C., Tolmie, J. L., Brown, D., Lunt, P., Winter, R. M., Marinoni, S., Stefanini, M., Brueton, L., Lehmann, A. R., & Higgs, D. R. (2001). Mutations in the general transcription factor TFIIH result in beta-thalassaemia in individuals with trichothiodystrophy. Human Molecular Genetics, 10(24), 2797–2802. https://doi.org/10.1093/hmg/10.24.2797
  20. Freson, K., Matthijs, G., Thys, C., Mariën, P., Hoylaerts, M. F., Vermylen, J., & Van Geet, C. (2002). Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Human Molecular Genetics, 11(2), 147–152. https://doi.org/10.1093/hmg/11.2.147
  21. Origa, R., Galanello, R., Perseu, L., Tavazzi, D., Domenica Cappellini, M., Terenzani, L., Forni, G. L., Quarta, G., Boetti, T., & Piga, A. (2009). Cholelithiasis in thalassemia major. European Journal of Haematology, 82(1), 22–25. https://doi.org/10.1111/j.1600-0609.2008.01162.x
  22. Origa, R., Satta, S., Matta, G., & Galanello, R. (2008). Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. British Journal of Haematology, 142(1), 143–145. https://doi.org/10.1111/j.1365-2141.2008.07175.x
  23. Origa, R., Fiumana, E., Gamberini, M. R., Armari, S., Mottes, M., Sangalli, A., Paglietti, E., Galanello, R., & Borgna-Pignatti, C. (2005). Osteoporosis in beta-thalassemia: Clinical and genetic aspects. Annals of the New York Academy of Sciences, 1054, 451–456. https://doi.org/10.1196/annals.1345.051
  24. Longo, F., Zecchina, G., Sbaiz, L., Fischer, R., Piga, A., & Camaschella, C. (1999). The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica, 84(9), 799–803.
  25. Ganz, T. (2013). Systemic Iron Homeostasis. Physiological Reviews, 93(4), 1721–1741. https://doi.org/10.1152/physrev.00008.2013
  26. McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., Hediger, M. A., Hentze, M. W., & Simpson, R. J. (2000). A Novel Duodenal Iron-Regulated Transporter, IREG1, Implicated in the Basolateral Transfer of Iron to the Circulation. Molecular Cell, 5(2), 299–309. https://doi.org/10.1016/S1097-2765(00)80425-6
  27. Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005). The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism, 1(3), 191–200. https://doi.org/10.1016/j.cmet.2005.01.003
  28. Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012). Non-transferrin bound iron: A key role in iron overload and iron toxicity. Biochimica et Biophysica Acta (BBA) - General Subjects, 1820(3), 403–410. https://doi.org/10.1016/j.bbagen.2011.07.014
  29. Nemeth, E., & Ganz, T. (2006). Regulation of Iron Metabolism by Hepcidin. Annual Review of Nutrition, 26(1), 323–342. https://doi.org/10.1146/annurev.nutr.26.061505.111303
  30. Zarghamian, P., Azarkeivan, A., Arabkhazaeli, A., Mardani, A., & Shahabi, M. (2020). Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy. BMC Medical Genetics, 21(1), 75. https://doi.org/10.1186/s12881-020-01011-3
  31. Ganz, T. (2011). Hepcidin and iron regulation, 10 years later. Blood, 117(17), 4425–4433. https://doi.org/10.1182/blood-2011-01-258467
  32. Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004). Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science, 306(5704), 2090–2093. https://doi.org/10.1126/science.1104742
  33. Kautz, L., Jung, G., Du, X., Gabayan, V., Chapman, J., Nasoff, M., Nemeth, E., & Ganz, T. (2015). Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood, 126(17), 2031–2037. https://doi.org/10.1182/blood-2015-07-658419
  34. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J., & Camaschella, C. (2008). The Serine Protease Matriptase-2 (TMPRSS6) Inhibits Hepcidin Activation by Cleaving Membrane Hemojuvelin. Cell Metabolism, 8(6), 502–511. https://doi.org/10.1016/j.cmet.2008.09.012
  35. Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T. A., Campagna, J. A., Chung, R. T., Schneyer, A. L., Woolf, C. J., Andrews, N. C., & Lin, H. Y. (2006). Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nature Genetics, 38(5), 531–539. https://doi.org/10.1038/ng1777
  36. Finberg, K. E. (2013). Regulation of systemic iron homeostasis: Current Opinion in Hematology, 20(3), 208–214. https://doi.org/10.1097/MOH.0b013e32835f5a47
  37. De Falco, L., Sanchez, M., Silvestri, L., Kannengiesser, C., Muckenthaler, M. U., Iolascon, A., Gouya, L., Camaschella, C., & Beaumont, C. (2013). Iron refractory iron deficiency anemia. Haematologica, 98(6), 845–853. https://doi.org/10.3324/haematol.2012.075515
  38. Abeywickrama, H. L. T. C., Rabindrakumar, M. S. K., Pathira Kankanamge, L. S., Thoradeniya, T., & Galhena, G. H. (2022). TMPRSS6 rs855791 polymorphism is associated with iron deficiency in a cohort of Sri Lankan pregnant women. Egyptian Journal of Medical Human Genetics, 23(1), 164. https://doi.org/10.1186/s43042-022-00377-8
  39. Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., … Piga, A. (2020). A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. New England Journal of Medicine, 382(13), 1219–1231. https://doi.org/10.1056/NEJMoa1910182
  40. Musallam, K. M., Taher, A. T., & Rachmilewitz, E. A. (2012). -Thalassemia Intermedia: A Clinical Perspective. Cold Spring Harbor Perspectives in Medicine, 2(7), a013482–a013482. https://doi.org/10.1101/cshperspect.a013482
  41. Cao, A., & Galanello, R. (2010). Beta-thalassemia. Genetics in Medicine, 12(2), 61–76. https://doi.org/10.1097/GIM.0b013e3181cd68ed
  42. Fucharoen, S., & Winichagoon, P. (2011). Haemoglobinopathies in southeast Asia. The Indian Journal of Medical Research, 134(4), 498–506.
  43. Khera, R., Singh, T., Khuana, N., Gupta, N., & Dubey, A. P. (2015). HPLC in Characterization of Hemoglobin Profile in Thalassemia Syndromes and Hemoglobinopathies: A Clinicohematological Correlation. Indian Journal of Hematology and Blood Transfusion, 31(1), 110–115. https://doi.org/10.1007/s12288-014-0409-x
  44. Bain, B. J. (Ed.). (2006). Haemoglobinopathy Diagnosis (1st ed.). Wiley. https://doi.org/10.1002/9780470988787
  45. Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2021). β-Thalassemias. New England Journal of Medicine, 384(8), 727–743. https://doi.org/10.1056/NEJMra2021838
  46. Old, J. M. (2003). Screening and genetic diagnosis of haemoglobin disorders. Blood Reviews, 17(1), 43–53. https://doi.org/10.1016/S0268-960X(02)00061-9
  47. Liu, J.-Z., Yan, M., Wang, L.-R., Wang, Z.-Y., Fan, Y.-P., Xiao, B., & Zhou, Y. (2008). Molecular Prenatal Diagnosis of α-Thalassemia Using Real-Time and Multiplex Polymerase Chain Reaction Methods. Hemoglobin, 32(6), 553–560. https://doi.org/10.1080/03630260802507600
  48. Xu, L., Mao, A., Liu, H., Gui, B., Choy, K. W., Huang, H., Yu, Q., Zhang, X., Chen, M., Lin, N., Chen, L., Han, J., Wang, Y., Zhang, M., Li, X., He, D., Lin, Y., Zhang, J., Cram, D. S., & Cao, H. (2020). Long-Molecule Sequencing. The Journal of Molecular Diagnostics, 22(8), 1087–1095. https://doi.org/10.1016/j.jmoldx.2020.05.004
  49. Colosimo, A., Gatta, V., Guida, V., Leodori, E., Foglietta, E., Rinaldi, S., Cappabianca, M. P., Amato, A., Stuppia, L., & Dallapiccola, B. (2011). Application of MLPA assay to characterize unsolved α-globin gene rearrangements. Blood Cells, Molecules, and Diseases, 46(2), 139–144. https://doi.org/10.1016/j.bcmd.2010.11.006
  50. Angelucci, E., Baronciani, D., & Lucarelli, G. (2000). Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. The New England Journal of Medicine.
  51. Anderson, L. (2001). Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal, 22(23), 2171–2179. https://doi.org/10.1053/euhj.2001.2822
  52. Brittenham, G. M. (2011). Iron-Chelating Therapy for Transfusional Iron Overload. N Engl j Med.
  53. Basu, S., Rahaman, M., Dolai, T. K., Shukla, P. C., & Chakravorty, N. (2023). Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review. Thalassemia Reports, 13(3), 179–194. https://doi.org/10.3390/thalassrep13030017
  54. Mobarra, N., Shanaki, M., Ehteram, H., Nasiri, H., Sahmani, M., Saeidi, M., Goudarzi, M., Pourkarim, H., & Azad, M. (2016). A Review on Iron Chelators in Treatment of Iron Overload Syndromes. International Journal of Hematology-Oncology and Stem Cell Research, 10(4), 239–247.
  55. Pinto, V., & Forni, G. (2020). Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series. International Journal of Molecular Sciences, 21(22), 8771. https://doi.org/10.3390/ijms21228771
  56. Higgs, D. R., Engel, J. D., & Stamatoyannopoulos, G. (2012). Thalassaemia. The Lancet, 379(9813), 373–383. https://doi.org/10.1016/S0140-6736(11)60283-3
  57. Morgan, M., & Schambach, A. (2025). Successful treatment of transfusion-dependent β-thalassemia: Multiple paths to reach potential cure. Signal Transduction and Targeted Therapy, 10(1), 55. https://doi.org/10.1038/s41392-025-02135-9
  58. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., De La Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., De Montalembert, M., Rondelli, D., … Corbacioglu, S. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054
  59. Rahmat, Z. S., Ali, M. H., Talha, M., & Hasibuzzaman, Md. A. (2024). FDA approval of Casgevy and Lyfgenia: A dual breakthrough in gene therapies for sickle cell disease. Annals of Medicine & Surgery, 86(9), 4966–4968. https://doi.org/10.1097/MS9.0000000000002409
  60. Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., Sabo, P. J., Vierstra, J., Voit, R. A., Yuan, G.-C., Porteus, M. H., Stamatoyannopoulos, J. A., Lettre, G., & Orkin, S. H. (2013). An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level. Science, 342(6155), 253–257. https://doi.org/10.1126/science.1242088
  61. Esrick, E. B., & Bauer, D. E. (2018). Genetic therapies for sickle cell disease. Seminars in Hematology, 55(2), 76–86. https://doi.org/10.1053/j.seminhematol.2018.04.014
  62. Huang, T., Jiang, H., Tang, G., Li, J., Huang, X., Huang, Z., & Zhang, H. (2025). Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: A systematic review and meta-analysis. Frontiers in Medicine, 11, 1480831. https://doi.org/10.3389/fmed.2024.1480831
  63. Taher, A., Farmakis, D., Porter, J., Cappellini, M.-D., & Musallam, K. (Eds.). (2025). Guidelines for the management of transfusion-dependent [beta]-thalassaemia (TDT) (5th edition). Thalassaemia International Federation.
  64. Carrancio, S., Markovics, J., Wong, P., Leisten, J., Castiglioni, P., Groza, M. C., Raymon, H. K., Heise, C., Daniel, T., Chopra, R., & Sung, V. (2014). An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. British Journal of Haematology, 165(6), 870–882. https://doi.org/10.1111/bjh.12838
  65. Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., Leboulch, P., Ribeil, J.-A., Arlet, J.-B., Coté, F., Courtois, G., Ginzburg, Y. Z., Daniel, T. O., Chopra, R., Sung, V., … Moura, I. C. (2014). An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nature Medicine, 20(4), 398–407. https://doi.org/10.1038/nm.3468
  66. Cappellini, M. D., Porter, J., Origa, R., Forni, G. L., Voskaridou, E., Galactéros, F., Taher, A. T., Arlet, J.-B., Ribeil, J.-A., Garbowski, M., Graziadei, G., Brouzes, C., Semeraro, M., Laadem, A., Miteva, D., Zou, J., Sung, V., Zinger, T., Attie, K. M., & Hermine, O. (2019). Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: A phase II, open-label, dose-finding study. Haematologica, 104(3), 477–484. https://doi.org/10.3324/haematol.2018.198887
  67. Lotinun, S., Scott Pearsall, R., C. Horne, W., & Baron, R. (2012). Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis. Current Molecular Pharmacology, 5(2), 195–204. https://doi.org/10.2174/1874467211205020195
  68. Oh, S. P., Yeo, C.-Y., Lee, Y., Schrewe, H., Whitman, M., & Li, E. (2002). Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes & Development, 16(21), 2749–2754. https://doi.org/10.1101/gad.1021802
  69. Raje, N., & Vallet, S. (2010). Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Current Opinion in Molecular Therapeutics, 12(5), 586–597.
  70. Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., Underwood, K. W., Grinberg, A. V., Quisel, J. D., Chopra, R., Pearsall, R. S., Seehra, J., & Kumar, R. (2014). Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nature Medicine, 20(4), 408–414. https://doi.org/10.1038/nm.3512
  71. Martinez, P. A., Suragani, R. N., Bhasin, M., Li, R., Pearsall, R. S., & Kumar, R. (2015). Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia. Blood, 126(23), 751–751. https://doi.org/10.1182/blood.V126.23.751.751
  72. Longo, F., Motta, I., Pinto, V., Piolatto, A., Ricchi, P., Tartaglione, I., & Origa, R. (2023). Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence. Journal of Clinical Medicine, 12(7), 2584. https://doi.org/10.3390/jcm12072584
  73. Musallam, K. M., & Taher, A. T. (2024). Luspatercept: A treatment for ineffective erythropoiesis in thalassemia. Hematology, 2024(1), 419–425. https://doi.org/10.1182/hematology.2024000567
  74. Guerra, A., Musallam, K. M., Taher, A. T., & Rivella, S. (2018). Emerging Therapies. Hematology/Oncology Clinics of North America, 32(2), 343–352. https://doi.org/10.1016/j.hoc.2017.11.002
  75. Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., Borgna-Pignatti, C., Zhang, X., Laadem, A., Sherman, M. L., & Attie, K. M. (2019). Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood, 133(12), 1279–1289. https://doi.org/10.1182/blood-2018-10-879247
  76. Suragani, R. N. V. S., Cawley, S. M., Li, R., Wallner, S., Alexander, M. J., Mulivor, A. W., Gardenghi, S., Rivella, S., Grinberg, A. V., Pearsall, R. S., & Kumar, R. (2014). Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood, 123(25), 3864–3872. https://doi.org/10.1182/blood-2013-06-511238
  77. Guerra, A., Oikonomidou, P. R., Sinha, S., Zhang, J., Lo Presti, V., Hamilton, C. R., Breda, L., Casu, C., La, P., Martins, A. C., Sendamarai, A. K., Fleming, M., & Rivella, S. (2019). Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia. Blood, 134(6), 568–572. https://doi.org/10.1182/blood.2019001057
  78. Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., Ganz, T., MacDonald, B., & Rivella, S. (2016). Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Blood, 128(2), 265–276. https://doi.org/10.1182/blood-2015-10-676742
  79. Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011). Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. Journal of Clinical Investigation, 121(12), 4880–4888. https://doi.org/10.1172/JCI57693
  80. Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T. (2012). Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 120(18), 3829–3836. https://doi.org/10.1182/blood-2012-07-440743
  81. Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., & Camaschella, C. (2012). Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Blood, 119(21), 5021–5029. https://doi.org/10.1182/blood-2012-01-401885
  82. Lob, H. E., Singh, N., Mohammadi, K., Ivanova, L., Crowell, B., Kim, H. J., Kravets, L., Das, N. M., Ray, Y., Kim, J. H., Rottey, S., Labriola-Tompkins, E., Hassan, H. E., Farrelly, L., Chin, H. F., Preda, M., Spencer Noakes, L., Saotome, K., Franklin, M., … Hatsell, S. J. (2025). A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans. JCI Insight, 10(12), e191813. https://doi.org/10.1172/jci.insight.191813
  83. Liu, G., Howell, H., Rudin, D., Arumugam, N., Jadia, J., Yang, H., & Savage, W. (2024). Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6. Blood, 144(Supplement 1), 1092–1092. https://doi.org/10.1182/blood-2024-203255
  84. Manolova, V., Nyffenegger, N., Flace, A., Altermatt, P., Varol, A., Doucerain, C., Sundstrom, H., & Dürrenberger, F. (2019). Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. Journal of Clinical Investigation, 130(1), 491–506. https://doi.org/10.1172/JCI129382
  85. Nakamura, T., Naguro, I., & Ichijo, H. (2019). Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochimica et Biophysica Acta (BBA) - General Subjects, 1863(9), 1398–1409. https://doi.org/10.1016/j.bbagen.2019.06.010
  86. Transferrin Saturation. (2016). In Advances in Clinical Chemistry (Vol. 75, pp. 71–97). Elsevier. https://doi.org/10.1016/bs.acc.2016.03.002
  87. Kleven, M. D., Jue, S., & Enns, C. A. (2018). Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms. Biochemistry, 57(9), 1552–1559. https://doi.org/10.1021/acs.biochem.8b00006
  88. Ganesh, S. K., Zakai, N. A., Van Rooij, F. J. A., Soranzo, N., Smith, A. V., Nalls, M. A., Chen, M.-H., Kottgen, A., Glazer, N. L., Dehghan, A., Kuhnel, B., Aspelund, T., Yang, Q., Tanaka, T., Jaffe, A., Bis, J. C. M., Verwoert, G. C., Teumer, A., Fox, C. S., … Lin, J.-P. (2009). Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nature Genetics, 41(11), 1191–1198. https://doi.org/10.1038/ng.466
  89. Forejtnikovà, H., Vieillevoye, M., Zermati, Y., Lambert, M., Pellegrino, R. M., Guihard, S., Gaudry, M., Camaschella, C., Lacombe, C., Roetto, A., Mayeux, P., & Verdier, F. (2010). Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood, 116(24), 5357–5367. https://doi.org/10.1182/blood-2010-04-281360
  90. Kuo, K., Layton, D., Al-Samkari, H., Kattamis, A., Sheth, S., Taher, A., Viprakasit, V., Chamberlain, C., Czapla, L., Gheuens, S., Jiang, L., Lynch, M., Tong, B., Uhlig, K., & Cappellini, M. (2021). ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology, Transfusion and Cell Therapy, 43, S20. https://doi.org/10.1016/j.htct.2021.10.035
CONTINUE EXPLORING

Most read articles by the same author(s)

Explore other published research by the authors of this article.